ArticleImmunologic research2026
Clustering of rheumatoid arthritis patients: an unsupervised machine learning approach for characterizing the TNFi response.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identifydistinct profiles of response to Tumor Necrosis Factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients using unsupervised machine learning to integrate clinical, demographic, and genetic data. A cohort of 294 RA patients was analyzed using hierarchical clustering techniques. Data collected included body mass index (BMI), adherence to physical activity, prevalence of comorbidities, seropositivity, Health Assessment Questionnaire (HAQ) scores, and genetic polymorphisms in TNF pathway. Responders to TNFi demonstrated a more favorable clinical profile, with a lower BMI (25.6 vs. 27.0; p = 0.03), higher physical activity adherence (56.6% vs. 33.3%; p < 0.01), reduced prevalence of comorbidities (69.8% vs. 82.4%; p = 0.02), and improved functionality (HAQ: 0.8 vs. 1.7; p < 0.01) compared with non-responders. The C allele of rs767455 was significantly more frequent among responders (74.4% vs. 62.4%; p = 0.04). Clustering analysis identified three distinct subgroups: a better prognosis group characterized by a 73.5% response rate, minimal use of combination therapies, high adherence to physical activity, and male predominance; a poorer therapeutic response group with 82.9% therapeutic failure, intensive medication use, and low exercise adherence; and an intermediate group. TNFi response in RA is multifactorial. Integrating clinical, demographic, and genetic data enables the identification of distinct patient profiles, supporting the development of personalized treatment strategies and the advancement of precision medicine in RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.